Chinese cancer drug developer Innovent Biologics, which has a number of PE backers, closed up on its Hong Kong trading debut, following a HK$3.3 billion ($421 million) IPO.
The company sold 215 million shares at HK$13.98 apiece, close to the top end of the indicative range. The stock closed up 18.6% on October 31 at HK$16.58. The offering was slightly oversubscribed,...
Novo Tellus Capital Partners has invested S$12 million ($8.8 million) in Procurri, a Singapore-listed provider of IT services and data center equipment.
Australia’s Anacacia Capital has realized the final exit from its debut fund with the sale of its majority stake in workplace equipment provider RIS Safety to domestic investor Bricktop Group.
Bain Capital has acquired a majority interest in the data center construction and maintenance division of Shenzhen-listed NetScience Technology for RMB990 million ($147 million).
Shukun, a Chinese company that provides artificial intelligence (AI) technology used in the treatment of cardiovascular diseases, has raised RMB200 million ($29 million) in a Series B round led by China Creation Ventures.